Roberto Ruiu

7PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCellular nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 28, 2023
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.

Roberto Ruiu, Chiara Cossu, Antonella Iacoviello

|Jun 27, 2022
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.

Antonino Di Lorenzo, Elisabetta Bolli, Roberto Ruiu

|Mar 06, 2021
Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.

Roberto Ruiu, Giuseppina Barutello, Maddalena Arigoni

|Mar 03, 2021
Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy.

Giulia Peppino, Roberto Ruiu, Maddalena Arigoni

|Jun 14, 2020
Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.

Laura Conti, Elisabetta Bolli, Antonino Di Lorenzo

|Dec 08, 2018
Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.

Gaetano Donofrio, Giulia Tebaldi, Stefania Lanzardo

Pageof 2

Frequent Collaborators

6 joint publications

Federica Cavallo

4 joint publications

Laura Conti

4 joint publications

Federica Riccardo

3 joint publications

Elena Quaglino